Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?

IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM
Martina Matovinović, Andrej Belančić, Juraj Jug, F. Mustač, Maja Sirovica, Mihovil Santini, Anja Bošnjaković, M. Lovrić, M. Lovrić Benčić
{"title":"Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?","authors":"Martina Matovinović, Andrej Belančić, Juraj Jug, F. Mustač, Maja Sirovica, Mihovil Santini, Anja Bošnjaković, M. Lovrić, M. Lovrić Benčić","doi":"10.3390/diabetology5010003","DOIUrl":null,"url":null,"abstract":"Background: Diabetes is the primary contributor to cardiovascular disease risk, and when combined with obesity, it further underscores the significance of cardiovascular risk assessment. Methods: A retrospective study of 64 patients with type 2 diabetes (T2D) and obesity on once-weekly subcutaneous semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes, and ASCVD score calculations. We compare the differences between groups (ASCVD: low + borderline + intermediate versus high-risk group; SCORE2/SCORE2-OP: low + moderate versus high + very high-risk group and SCORE2-Diabetes: low + moderate versus high + very high-risk group) in terms of change from baseline in body mass index (BMI) and HbA1c and weight loss outcomes. Results: Patients in the high-risk group, according to ASCVD risk score, had statistically better results in weight loss ≥ 3%, ≥5%, and ≥10% compared to ASCVD low + borderline + intermediate and without difference regarding HbA1c. According to SCORE2/SCORE2-OP, the high + very high-risk group had statistically better HbA1c and weight loss results but only for ≥5% versus the low + moderate risk group. Based on the score SCORE2-Diabetes, the high + very high-risk group had statistically significant better results in lowering HbA1c and weight loss but only for ≥5% versus the low + moderate risk group. Conclusions: To the best of our knowledge, this study represents the initial investigation linking glycemic control and weight reduction outcomes in individuals with T2D and obesity treated with once-weekly semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes and ASCVD score calculations.","PeriodicalId":72798,"journal":{"name":"Diabetology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/diabetology5010003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Diabetes is the primary contributor to cardiovascular disease risk, and when combined with obesity, it further underscores the significance of cardiovascular risk assessment. Methods: A retrospective study of 64 patients with type 2 diabetes (T2D) and obesity on once-weekly subcutaneous semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes, and ASCVD score calculations. We compare the differences between groups (ASCVD: low + borderline + intermediate versus high-risk group; SCORE2/SCORE2-OP: low + moderate versus high + very high-risk group and SCORE2-Diabetes: low + moderate versus high + very high-risk group) in terms of change from baseline in body mass index (BMI) and HbA1c and weight loss outcomes. Results: Patients in the high-risk group, according to ASCVD risk score, had statistically better results in weight loss ≥ 3%, ≥5%, and ≥10% compared to ASCVD low + borderline + intermediate and without difference regarding HbA1c. According to SCORE2/SCORE2-OP, the high + very high-risk group had statistically better HbA1c and weight loss results but only for ≥5% versus the low + moderate risk group. Based on the score SCORE2-Diabetes, the high + very high-risk group had statistically significant better results in lowering HbA1c and weight loss but only for ≥5% versus the low + moderate risk group. Conclusions: To the best of our knowledge, this study represents the initial investigation linking glycemic control and weight reduction outcomes in individuals with T2D and obesity treated with once-weekly semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes and ASCVD score calculations.
根据 SCORE2、SCORE2-糖尿病和 ASCVD 计算结果,2 型糖尿病和肥胖症患者的低风险亚组和高风险亚组之间的塞马鲁肽疗效是否存在差异?
背景:糖尿病是导致心血管疾病风险的主要因素,如果合并肥胖症,则进一步凸显了心血管风险评估的重要性。研究方法对64名2型糖尿病(T2D)和肥胖症患者进行回顾性研究,这些患者每周服用一次皮下注射的塞马鲁肽,根据SCORE2/SCORE2-OP、SCORE2-糖尿病和ASCVD评分计算得出的心血管风险类别进行分层。我们比较了各组(ASCVD:低风险组 + 边缘 + 中度风险组与高风险组;SCORE2/SCORE2-OP:低风险组 + 中度风险组与高风险组 + 极高风险组;SCORE2-糖尿病:低风险组 + 中度风险组与高风险组 + 极高风险组)在体重指数 (BMI) 和 HbA1c 以及体重减轻结果与基线相比的变化差异。结果根据 ASCVD 风险评分,与 ASCVD 低度 + 边缘 + 中度组相比,高风险组患者在体重减轻≥3%、≥5% 和≥10% 方面有更好的统计结果,而在 HbA1c 方面没有差异。根据 SCORE2/SCORE2-OP,高风险组和极高风险组的 HbA1c 和体重减轻结果在统计学上更好,但与低风险组和中等风险组相比,仅在≥5% 时有更好的结果。根据 SCORE2-Diabetes 评分,高风险+极高风险组在降低 HbA1c 和减轻体重方面的结果在统计学上明显优于低风险+中度风险组,但仅在降低 HbA1c 和减轻体重≥5%方面优于低风险+中度风险组。结论:据我们所知,本研究是首次对使用每周一次的塞马鲁肽治疗的 T2D 和肥胖症患者的血糖控制和体重减轻效果进行研究,这些患者的血糖控制和体重减轻效果是根据 SCORE2/SCORE2-OP、SCORE2-糖尿病和 ASCVD 评分计算得出的心血管风险类别进行分层的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信